Figure 1.
Figure 1. PD-L1 protein signature in B-cell lymphomas. (A) PD-L1 expression analyzed by RPPA analysis in 10 representative non-GCB DLBCL, 20 representative GCB DLBCL, 10 representative MCL, and 5 representative EBV+ B cell lymphoma (BCL) cell lines. Flow cytometry plots show coexpression of PD-L1 and CD20 in 3 representative non-GCB DLBCL cell lines (HBL-1, LP, and WP) and the RC GCB DLBCL cell line, which was used as a negative control for PD-L1 and positive control for CD20 (inset). *EBV+ MCL cell line. (B) RPPA heat map showing a cluster based on high PD-L1 expression level on all cell lines analyzed. (C) Proteins within the cluster and their known cellular functions, analyzed by ingenuity pathway analysis.

PD-L1 protein signature in B-cell lymphomas. (A) PD-L1 expression analyzed by RPPA analysis in 10 representative non-GCB DLBCL, 20 representative GCB DLBCL, 10 representative MCL, and 5 representative EBV+ B cell lymphoma (BCL) cell lines. Flow cytometry plots show coexpression of PD-L1 and CD20 in 3 representative non-GCB DLBCL cell lines (HBL-1, LP, and WP) and the RC GCB DLBCL cell line, which was used as a negative control for PD-L1 and positive control for CD20 (inset). *EBV+ MCL cell line. (B) RPPA heat map showing a cluster based on high PD-L1 expression level on all cell lines analyzed. (C) Proteins within the cluster and their known cellular functions, analyzed by ingenuity pathway analysis.

Close Modal

or Create an Account

Close Modal
Close Modal